Fluphenazine: A 1959 antipsychotic finding new life in cancer research and beyond
In short: Originally approved in 1959 to treat schizophrenia by balancing brain dopamine, fluphenazine is a high-potency antipsychotic with a complex profile. Beyond its psychiatric use, recent research suggests potential as a repurposed anticancer agent, though its clinical application remains balanced against significant side effects like movement disorders and metabolic changes.
Fluphenazine belongs to the phenothiazine class of antipsychotics. It functions primarily as a dopamine antagonist, blocking D2 and D1 receptors in the brain to help regulate mood and behavior. Since its FDA approval in 1959, it has become a staple in treating chronic psychoses. By 1968, it became the first injectable antipsychotic approved in the United States, offering a depot delivery system that remains on the World Health Organization's List of Essential Medicines for its role in improving treatment adherence.
The drug's mechanism is broad, extending beyond dopamine to block adrenergic, muscarinic, and histaminergic receptors. This wide-reaching activity contributes to a range of side effects, including drowsiness, dry mouth, and the potentially permanent movement disorder known as tardive dyskinesia. Because it can affect body temperature regulation and increase sensitivity to sunlight, patients are often advised to take specific precautions. Furthermore, its use is associated with metabolic shifts, such as increased blood sugar and elevated prolactin levels, which can lead to hormonal changes.
Recent scientific interest has shifted toward drug repositioning, exploring whether fluphenazine might serve purposes beyond psychiatry. Studies on gastric cancer cells and mouse models indicate that fluphenazine may inhibit tumor growth and migration, particularly when combined with the chemotherapy drug cisplatin. Researchers suggest that the drug might also contribute to skin depigmentation in some patients by exerting cytotoxic effects on melanocytes. While these findings are promising, they highlight the necessity of a nuanced, interdisciplinary approach to managing patients who may face both psychiatric and dermatological or oncological challenges.
Clinical use of fluphenazine requires careful monitoring. Because steady-state concentrations vary significantly between individuals due to differences in metabolism and absorption, finding the optimal dose is a delicate process. Experts recommend gradual withdrawal when discontinuing the medication to avoid relapse or acute withdrawal symptoms. As research continues to uncover new potential applications, the drug remains a subject of ongoing study, balancing its established psychiatric utility against its complex biological footprint.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Fluphenazine (Prolixin): Uses & Side Effects
- Also: Fluphenazine
- Also: Anticancer Effects of Fluphenazine Alone and in Combination with Cisplatin in Gastric Cancer Cells and a Mouse Xenograft Model.
To cite this card, link to https://intellectplus.co.uk/app/health-fluphenazine.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics
